http://nz.biz.yahoo.com//091019/24/f6zv.html
Research and Markets(http://www.researchandmarkets.com/research/1ef2a4/malaysia_pharmaceu)
has announced the addition of the "Malaysia
Pharmaceuticals and Healthcare Report Q4 2009" report to their
offering.
The Malaysia Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Malaysia's
pharmaceuticals and healthcare industry.
In the Business Environment Rating (BER) matrix for Q409, Malaysia
considerably improved its position in the Asia Pacific matrix, and is
now ranked fifth out of the 15 key regional markets. Key attractions of
the Malaysian pharmaceutical market are the government's encouragement
of the biotechnology sector and the forecast steady annual growth in its
pharmaceutical market. On the other hand, per-capita pharmaceutical
consumption is quite low, especially due to high out-of-pocket payment
levels, which make the market vulnerable to the current economic crisis.
Nevertheless, we forecast that the market will post a compound annual
growth rate (CAGR) of 7.65% in local currency terms, rising - at
consumer prices - from MYR4.12bn (US$1.22bn) in 2008 to MYR5.96bn
(US$1.96bn) in 2013.
Boosted by considerable encouragement from the government, the generic
sector will gain in terms of volume, although generics will only gain a
small percentage of the total market due to their competitive prices.
Patent expirations will have a considerable impact on the performance of
the generic sector in the coming years. In August 2009, Indian Ranbaxy
launched cardiovascular treatment Covance (losartan), which will be
manufactured locally. Given the low cost of the product and the unmet
medical need, the author expects prescribers' uptake of the drug to be
rapid.
In addition to cannibalising sales of the originator product - Merck &
Co's Cozaar - Covance will gain market share at the expense of Diovan
(valsartan), Aprovel (irbesartan) and Micardis (telmisartan).
Although the operating environment for foreign companies remains
challenging - with medical devices specialist B Braun Medical Industries
mulling the relocation of its manufacturing facilities from Malaysia to
Indonesia - clinical trials and biotechnology continue to be considered
areas of growth. Indian Veeda Clinical Research recently created its
South East Asia office in Malaysia, while also signing a collaborative
agreement with the Malaysian Ministry of Health, with a view to opening
an early clinical trials centre. Similarly, a subsidiary of US
biotechnology firm Actis Biologics was in the process of securing funds
for the creation of a biotech park (to be named Biocity) in Melaka,
Malaysia.
In terms of recent epidemiological developments, the burden of digestive
system disorders - including peptic ulcers, irritable bowel syndrome
(IBS) and colon cancer - in the country is growing. In fact, in 2007,
they were the seventh-most common causes of both morbidity and
mortality, indicating a significant unmet medical need. Recently, the
country has also been affected by the globally-spreading swine flu
epidemic. By early August 2009, the human death toll rose to 44, with
the Ministry of Health commencing a public education campaign on the
spread of the A (H1N1) virus. The current stock of antivirals is
expected to be supplemented by an additional MYR20m (US$6mn) worth of
medicines, while all healthcare institutions have also been ordered to
utilise rapid influenza screening tests.
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Business Environment Ratings
Malaysia - Market Summary
Regulatory Regime
Industry Trends And Developments
Industry Forecast Scenario
Competitive Landscape
Company Profiles
Country Snapshot: Malaysia Demographic Data
Methodology
Companies Mentioned:
GlaxoSmithKline (GSK)
Pfizer
Novartis
Merck & Co
Sanofi-Aventis
Ranbaxy Malaysia
Eli Lilly Malaysia
Pharmaniaga
Asia Pharmaceutical Products (APP)
Prime Pharmaceutical
Bumimedic
Hovid
Chemical Company of Malaysia (CCM)
Kotra Pharma
YSP Southeast Holding
For more information visit http://www.researchandmarkets.com/research/1ef2a4/malaysia_pharmaceu
Contact:Research and MarketsLaura Wood, Senior Manager,press@researchandmarkets.comU.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
|
